Novel pancreatic cancer vaccines could unleash the army within

Cancer Control

Volumn 21, Issue 3, 2014, Pages 242-246

  Springett, Gregory M ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALGENPANTUCEL L; CANCER VACCINE; CRS 207; FLUOROURACIL; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; ARTICLE; CANCER IMMUNOTHERAPY; CHEMORADIOTHERAPY; CYTOKINE RESPONSE; CYTOTOXIC T LYMPHOCYTE; DELAYED HYPERSENSITIVITY; DISEASE FREE SURVIVAL; DRUG DOSE ESCALATION; HUMAN; HYPERACUTE GRAFT REJECTION; INJECTION SITE REACTION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MAJOR HISTOCOMPATIBILITY COMPLEX; MESOTHELIOMA; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; REGULATORY T LYMPHOCYTE; SURVIVAL RATE; TUMOR REGRESSION; TUMOR REJECTION; CARCINOMA, PANCREATIC DUCTAL; IMMUNOLOGY; PANCREATIC NEOPLASMS; PHASE 2 CLINICAL TRIAL (TOPIC);

CANCER VACCINES; CARCINOMA, PANCREATIC DUCTAL; CLINICAL TRIALS, PHASE II AS TOPIC; HUMANS; PANCREATIC NEOPLASMS;

EID: 84903156000     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327481402100311     Document Type: Article

References (22)

1. Howlader N, Noone AM, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2011. Bethesda, MD: National Cancer Institute. Published November 2013, modified April 2014. http://seer.cancer.gov/csr/1975_2011. Accessed April 28, 2014.
2. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18): 1691-1703.
3. Conroy T, Desseigne F, Ychou M. et al; Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817-1825.
4. Antoniou G, Kountourakis P, Papadimitriou K, et al. Adjuvant therapy for resectable pancreatic adenocarcinoma: review of the current treatment approaches and future directions. Cancer Treat Rev. 2014;40(1):78-85.
5. Hardacre JM, Mulcahy M, Small W, et al. Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study. J Gastrointest Surg. 2013;17(1):94-101.
6. Le DT, Wang-Gillam A, Picozziet V Jr, et al. A phase 2, randomized trial of GVAX pancreas and CRS-207 immunotherapy versus GVAX alone in patients with metastatic pancreatic adenocarcinoma: updated results. J Clin Oncol. 2014;32(3 suppl):177.
7. Bazhin AV, Shevchenko I, Umansky V, et al. Two immune faces of pancreatic adenocarcinoma: possible implication for immunotherapy. Cancer Immunol Immunother. 2014;63(1):59-65.
8. Fukunaga A, Miyamoto M, Cho Y, et al. CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas. 2004;28(1):e26-e31.
9. Ryschich E, Nötzel T, Hinz U, et al. Control of T-cell-mediated immune response by HLA class I in human pancreatic carcinoma. Clin Cancer Res. 2005;11(2 pt 1):498-504.
10. Heller A, Zörnig I, Müller T, et al. Immunogenicity of SEREX-identified antigens and disease outcome in pancreatic cancer. Cancer Immunol Immunother. 2010;59(9):1389-1400.
11. Shevchenko I, Karakhanova S, Soltek S, et al. Low-dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer. Int J Cancer. 2013;133(1):98-107.
12. Gabitass RF, Annels NE, Stocken DD, et al. Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol Immunother. 2011;60(10):1419-1430.
13. Greten TF, Jaffee EM. Cancer vaccines. J Clin Oncol. 1999;17(3): 1047-1060.
14. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1-10.
15. Vogelstein B, Papadopoulos N, Velculescu VE, et al. Cancer genome landscapes. Science. 2013;339(6127):1546-1558.
16. Biankin AV, Waddell N, Kassahn KS, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature. 2012;491(7424):399-405.
17. Galili U. The alpha-gal epitope and the anti-Gal antibody in xenotransplantation and in cancer immunotherapy. Immunol Cell Biol. 2005;83(6): 674-686.
18. Rossi GR, Hardacre JM, Mulcahy MF, et al. Effect of algenpantucel-L immunotherapy for pancreatic cancer on anti-mesothelin antibody (Ab) titers and correlation with improved overall survival. J Clin Oncol. 2013;31 (15 suppl):3007.
19. Jaffee EM, Hruban RH, Biedrzycki B, et al. Novel allogeneic granulocyte- macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol. 2001;19(1):145-156.
20. Lutz E, Yeo CJ, Lillemoe KD, et al. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A phase II trial of safety, efficacy, and immune activation. Ann Surg. 2011;253(2):328-335.
21. Le DT, Brockstedt DG, Nir-Paz R, et al. A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS- 207) for advanced cancers: phase I studies of safety and immune induction. Clin Cancer Res. 2012;18(3):858-868.
22. Le DT, Jaffee EM. Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective. Cancer Res. 2012;72(14): 3439-3444.